{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:12:07Z","timestamp":1784866327477,"version":"3.55.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2016,12,12]],"date-time":"2016-12-12T00:00:00Z","timestamp":1481500800000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>It has been estimated that $154 million per year will be required during 2015\u20132020 to continue the Global Programme to Eliminate Lymphatic Filariasis (GPELF). In light of this, it is important to understand the program\u2019s current value. Here, we evaluate the cost-effectiveness and cost-benefit of the preventive chemotherapy that was provided under the GPELF between 2000 and 2014. In addition, we also investigate the potential cost-effectiveness of hydrocele surgery.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods.<\/jats:title>\n                  <jats:p>Our economic evaluation of preventive chemotherapy was based on previously published health and economic impact estimates (between 2000 and 2014). The delivery costs of treatment were estimated using a model developed by the World Health Organization. We also developed a model to investigate the number of disability-adjusted life years (DALYs) averted by a hydrocelectomy and identified the cost threshold under which it would be considered cost-effective.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>The projected cost-effectiveness and cost-benefit of preventive chemotherapy were very promising, and this was robust over a wide range of costs and assumptions. When the economic value of the donated drugs was not included, the GPELF would be classed as highly cost-effective. We projected that a typical hydrocelectomy would be classed as highly cost-effective if the surgery cost less than $66 and cost-effective if less than $398 (based on the World Bank\u2019s cost-effectiveness thresholds for low income countries).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions.<\/jats:title>\n                  <jats:p>Both the preventive chemotherapy and hydrocele surgeries provided under the GPELF are incredibly cost-effective and offer a very good investment in public health.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciw835","type":"journal-article","created":{"date-parts":[[2016,12,8]],"date-time":"2016-12-08T12:05:45Z","timestamp":1481198745000},"page":"728-735","source":"Crossref","is-referenced-by-count":14,"title":["Investment Success in Public Health: An Analysis of the Cost-Effectiveness and Cost-Benefit of the Global Programme to Eliminate Lymphatic Filariasis"],"prefix":"10.1093","volume":"64","author":[{"given":"Hugo C.","family":"Turner","sequence":"first","affiliation":[{"name":"London Centre for Neglected Tropical Disease Research 1 , and"},{"name":"Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, St Marys Campus, Imperial College London 2 , United Kingdom ;"},{"name":"Oxford University Clinical Research Unit 3 , Wellcome Trust Major Overseas Programme, Ho Chi Minh City , ;","place":["Vietnam"]},{"name":"Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford 4 , ;","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison A.","family":"Bettis","sequence":"additional","affiliation":[{"name":"London Centre for Neglected Tropical Disease Research 1 , and"},{"name":"Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, St Marys Campus, Imperial College London 2 , United Kingdom ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K.","family":"Chu","sequence":"additional","affiliation":[{"name":"Neglected Tropical Diseases Support Center, Task Force for Global Health 5 , Decatur , and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"McFarland","sequence":"additional","affiliation":[{"name":"Rollins School of Public Health, Emory University 6 , Atlanta, Georgia ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J.","family":"Hooper","sequence":"additional","affiliation":[{"name":"Neglected Tropical Diseases Support Center, Task Force for Global Health 5 , Decatur , and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunny D.","family":"Mante","sequence":"additional","affiliation":[{"name":"Urology Unit 7 , 37 Military Hospital, Korle-Bu, Accra , ;","place":["Ghana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Fitzpatrick","sequence":"additional","affiliation":[{"name":"Department of Control of Neglected Tropical Diseases, World Health Organization 8 , Geneva , ; and","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Bradley","sequence":"additional","affiliation":[{"name":"Global Health Programs, GlaxoSmithKline 9 , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,12,10]]},"reference":[{"key":"2024111411402788100_CIT0001","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0065-308X(05)61010-X","article-title":"Lymphatic filariasis: treatment, control and elimination","volume":"61","author":"Ottesen","year":"2006","journal-title":"Adv Parasitol"},{"key":"2024111411402788100_CIT0002","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1371\/journal.pntd.0000317","article-title":"The global programme to eliminate lymphatic filariasis: health impact after 8 years","volume":"2","author":"Ottesen","year":"2008","journal-title":"PLoS Negl Trop Dis"},{"key":"2024111411402788100_CIT0003","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1475-2883-6-2","article-title":"Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature","volume":"6","author":"Addiss","year":"2007","journal-title":"Filaria J"},{"key":"2024111411402788100_CIT0004","volume-title":"Global Programme to Eliminate Lymphatic Filariasis: progress report 2000\u20132009 and strategic plan 2010\u20132020","author":"World Health Organization","year":"2010"},{"key":"2024111411402788100_CIT0005","volume-title":"Accelerating work to overcome the global impact of neglected tropical diseases\u2014A roadmap for implementation","author":"World Health Organization"},{"issue":"38","key":"2024111411402788100_CIT0006","first-page":"489","article-title":"489 Global programme to eliminate lymphatic filariasis: progress report, 2014","volume":"90","author":"World Health Organization","year":"2015","journal-title":"Wkly Epidemiol Rec"},{"key":"2024111411402788100_CIT0007","volume-title":"Investing to overcome the global impact of neglected tropical diseases: third WHO report on neglected tropical diseases","author":"World Health Organization","year":"2015"},{"key":"2024111411402788100_CIT0008","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40249-016-0147-4","article-title":"The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000\u20132014)","volume":"5","author":"Turner","year":"2016","journal-title":"Infect Dis Poverty"},{"key":"2024111411402788100_CIT0009","author":"Fitzpatrick","year":"2016"},{"key":"2024111411402788100_CIT0010","volume-title":"Benchmarks for the cost per person of mass treatment against neglected tropical diseases"},{"key":"2024111411402788100_CIT0028","author":"US. Bureau of Labor Statistics: CPI Inflation Calculator. Available at: http:\/\/www.bls.gov\/data\/inflation_calculator.htm"},{"key":"2024111411402788100_CIT0029","volume-title":"PCT databank: Lymphatic filariasis","author":"World Health Organisation"},{"key":"2024111411402788100_CIT0011","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/01.ju.0000103636.61790.43","article-title":"A population based assessment of complications following outpatient hydrocelectomy and spermatocelectomy","volume":"171","author":"Kiddoo","year":"2004","journal-title":"J Urol"},{"key":"2024111411402788100_CIT0012","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0001-706X(01)00159-0","article-title":"Consequences of hydrocele and the benefits of hydrocelectomy: a qualitative study in lymphatic filariasis endemic communities on the coast of Ghana","volume":"80","author":"Ahorlu","year":"2001","journal-title":"Acta Trop"},{"key":"2024111411402788100_CIT0013","doi-asserted-by":"crossref","DOI":"10.1596\/0-1952-0890-0","volume-title":"World Development Report 1993: Investing in Health","author":"World Bank","year":"1993"},{"key":"2024111411402788100_CIT0014","author":"Coffeng","year":"2013"},{"key":"2024111411402788100_CIT0015","volume-title":"Threshold values for intervention cost-effectiveness by region","author":"WHO-CHOICE"},{"key":"2024111411402788100_CIT0016","volume-title":"WHO, Smithkline Beechamto cooperate on Elephatiasis elmination","author":"World Health Organization Press Office"},{"key":"2024111411402788100_CIT0017","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40249-015-0068-7","article-title":"The burden of mental health in lymphatic filariasis","volume":"4","author":"Ton","year":"2015","journal-title":"Infect Dis Poverty"},{"key":"2024111411402788100_CIT0018","volume-title":"Study of cost per treatment with ivermectin using the CDTI strategy","author":"McFarland","year":"2005"},{"key":"2024111411402788100_CIT0019","article-title":"Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under varying levels of mass drug administration scale-up and geographic coverage","volume":"1: e000021","author":"Stone","year":"2016","journal-title":"BMJ Global Health"},{"key":"2024111411402788100_CIT0020","doi-asserted-by":"crossref","first-page":"877","DOI":"10.4269\/ajtmh.16-0286","article-title":"Economic costs and benefits of a community-based lymphedema management program for lymphatic filariasis in Odisha State, India","volume":"95","author":"Stillwaggon","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"2024111411402788100_CIT0021","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/civ882","article-title":"Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis","volume":"62","author":"Thomsen","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024111411402788100_CIT0022","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40273-014-0162-x","article-title":"Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines","volume":"32","author":"Newall","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"2024111411402788100_CIT0023","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2471\/BLT.14.138206","article-title":"Thresholds for the cost-effectiveness of interventions: alternative approaches","volume":"93","author":"Marseille","year":"2015","journal-title":"Bull World Health Organ"},{"key":"2024111411402788100_CIT0024","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/10899580-000000000-00000","article-title":"Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules","volume":"27","author":"Shillcutt","year":"2009","journal-title":"Pharmacoeconomics"},{"key":"2024111411402788100_CIT0025","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(09)61422-7","article-title":"Socioeconomic aspects of neglected tropical diseases","volume":"375","author":"Conteh","year":"2010","journal-title":"Lancet"},{"key":"2024111411402788100_CIT0026","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.pt.2014.10.001","article-title":"Neglected tools for neglected diseases: mathematical models in economic evaluations","volume":"30","author":"Turner","year":"2014","journal-title":"Trends Parasitol"},{"key":"2024111411402788100_CIT0027","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/inthealth\/ihu052","article-title":"Development assistance for neglected tropical diseases: progress since 2009","volume":"6","author":"Liese","year":"2014","journal-title":"Int Health"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/64\/6\/728\/13803352\/ciw835.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/64\/6\/728\/13803352\/ciw835.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T11:53:49Z","timestamp":1731585229000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/64\/6\/728\/2670371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,10]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,12,10]]},"published-print":{"date-parts":[[2017,3,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciw835","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,3,15]]},"published":{"date-parts":[[2016,12,10]]}}}